HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David DeShazer Selected Research

Glanders

10/2012Distinct human antibody response to the biological warfare agent Burkholderia mallei.
5/2012Humoral immune responses in a human case of glanders.
2/2011Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides.
1/2010Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis.
1/2010Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages.
9/2008A disruption of ctpA encoding carboxy-terminal protease attenuates Burkholderia mallei and induces partial protection in CD1 mice.
3/2005Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice.
9/2004Structural flexibility in the Burkholderia mallei genome.
10/2003Characterization of experimental equine glanders.
5/2002Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David DeShazer Research Topics

Disease

10Glanders
10/2012 - 05/2002
8Melioidosis
01/2022 - 06/2004
7Infections
12/2020 - 07/2002
1Burkholderia Infections
01/2019
1Disease Progression
03/2015
1Bacterial Infections (Bacterial Infection)
07/2014

Drug/Important Bio-Agent (IBA)

5VaccinesIBA
11/2019 - 05/2002
4Proteins (Proteins, Gene)FDA Link
12/2020 - 10/2012
2Biological Warfare AgentsIBA
01/2022 - 09/2004
2Anti-Bacterial Agents (Antibiotics)IBA
11/2019 - 07/2014
2LipopolysaccharidesIBA
01/2019 - 07/2002
2Subunit VaccinesIBA
01/2018 - 02/2011
2AerosolsIBA
03/2015 - 03/2005
2Type VI Secretion SystemsIBA
08/2014 - 01/2010
2Virulence Factors (Pathogenicity Factors)IBA
07/2014 - 01/2010
1CytokinesIBA
12/2020
1ChemokinesIBA
12/2020
1Attenuated VaccinesIBA
11/2019
1Type III Secretion SystemsIBA
08/2014
1Type II Secretion SystemsIBA
08/2014
1Proteasome InhibitorsIBA
07/2014
1LipopeptidesIBA
07/2014
1Peptides (Polypeptides)IBA
10/2012
1AntibodiesIBA
10/2012
1Immunoglobulin A (IgA)IBA
05/2012
1Immunoglobulin M (IgM)IBA
05/2012
1Immunoglobulin G (IgG)IBA
05/2012
1AntigensIBA
05/2012
14- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA
09/2008
1Capsules (Microcapsules)IBA
03/2005
1Branched-Chain Amino AcidsIBA
03/2005
1Biological ProductsIBA
06/2004
1O Antigens (O Antigen)IBA
07/2002

Therapy/Procedure

1Immunotherapy
01/2019
1Therapeutics
07/2014